This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by COMI, R. J. Articles by GORDEN, P. Search for Related Content PubMed PubMed Citation Articles by COMI, R. J. Articles by GORDEN, P.

The Response of Serum Growth Hormone Levels to the Long-Acting Somatostatin Analog SMS 201-995 in Acromegaly

Diabetes Branch, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health Bethesda, Maryland 20892

Address requests for reprints to: Dr. Richard J. Comi, Diabetes Branch, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Building 20, Room 9N222, Bethesda, Maryland 20892.

SMS 201–995 (SMS) is a long-acting analog of somatostatin. We studied the effect of SMS (50–100 µg, sc, every 8 h) on serum GH in five patients with acromegaly. Serum GH decreased significantly in four of the five patients 4 h after SMS treatment. In two of the four patients, this reduction was not sustained for 7 h, but sustained reduction to normal GH concentrations did occur in the two patients who had basal serum GH levels below 15 ng/ml. In the two patients whose responses were not sustained for 7 h, a higher dose of SMS did not cause sustained reduction in GH. SMS was well tolerated, except for one episode of elevated serum aminotransferase levels. These results indicate that SMS-induced reductions in serum GH in patients with acromegaly are often not sustained despite SMS administration every 8 h and indicate that the insufficient duration of effect may limit its therapeutic efficacy.

Received May 5, 1986.

This article has been cited by other articles:

				K. Y. Ho, A. J. Weissberger, P. Marbach, and L. Lazarus Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly: Effects of Dose and Frequency and Long-Term Safety Ann Intern Med, February 1, 1990; 112(3): 173 - 181. [Abstract] [PDF]

				S. Barakat and S. Melmed Reversible Shrinkage of a Growth Hormone-Secreting Pituitary Adenoma by a Long-Acting Somatostatin Analogue, Octreotide Arch Intern Med, June 1, 1989; 149(6): 1443 - 1445. [Abstract] [PDF]

				P. Gorden, R. J. Comi, P. N. Maton, and V. L. W. Go Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut Ann Intern Med, January 1, 1989; 110(1): 35 - 50. [Abstract] [PDF]